Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.
Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee. Iribarren JA, et al. Among authors: torralba m. Enferm Infecc Microbiol Clin. 2016 Oct;34(8):517-23. doi: 10.1016/j.eimc.2016.02.025. Epub 2016 Apr 5. Enferm Infecc Microbiol Clin. 2016. PMID: 27056581 Review.
High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients).
Arribas JR, Pulido F, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Del Palacio A, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Arribas JR, et al. Among authors: torralba m. AIDS. 2002 Jul 26;16(11):1554-6. doi: 10.1097/00002030-200207260-00014. AIDS. 2002. PMID: 12131195 Clinical Trial.
NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F, Torralba M. Pulido F, et al. Among authors: torralba m. J HIV Ther. 2002 Nov;7 Suppl 2:S3-16. J HIV Ther. 2002. PMID: 12735215 Review. English, Spanish. No abstract available.
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Pulido F, et al. Among authors: torralba m. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50. doi: 10.1097/00126334-200404010-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15097150
Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.
Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee. Iribarren JA, et al. Among authors: torralba m. Enferm Infecc Microbiol Clin. 2016 Oct;34(8):516.e1-516.e18. doi: 10.1016/j.eimc.2016.02.004. Epub 2016 Mar 11. Enferm Infecc Microbiol Clin. 2016. PMID: 26976381
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997-2017).
Beltrán-Pavez C, Gutiérrez-López M, Rubio-Garrido M, Valadés-Alcaraz A, Prieto L, Ramos JT, Jiménez De Ory S, Navarro M, Díez-Romero C, Pulido F, Valencia E, Holguín Á; Madrid Cohort of HIV-Infected Children integrated in the Pediatric Branch of the Spanish National AIDS Network (CoRISpe). Beltrán-Pavez C, et al. Sci Rep. 2020 Oct 9;10(1):16891. doi: 10.1038/s41598-020-70861-x. Sci Rep. 2020. PMID: 33037235 Free PMC article.
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.
Jiménez de Ory S, Beltrán-Pavez C, Gutiérrez-López M, Santos MDM, Prieto L, Sainz T, Guillen S, Aguilera-Alonso D, Díez C, Bernardino JI, Mellado MJ, Ramos JT, Holguín Á, Navarro M; Paediatric Cohort of the Spanish National AIDS Network (CoRISpe and CoRISpe-FARO). Jiménez de Ory S, et al. J Antimicrob Chemother. 2021 Jun 18;76(7):1886-1892. doi: 10.1093/jac/dkab080. J Antimicrob Chemother. 2021. PMID: 33734374 Free PMC article.
Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir.
Ramirez ML, Vargas FX, González-Garcia J, Quereda C, Pérez-Elías MJ, de Cea AM, Barros C, Condés E, Moreno JS, Santos I, Torralba M, Aldamiz-Echevarria T, Moreno A. Ramirez ML, et al. Among authors: torralba m. AIDS. 2014 Oct 23;28(16):2487-9. doi: 10.1097/QAD.0000000000000425. AIDS. 2014. PMID: 25265233 No abstract available.
Women, men, and HIV infection: One virus, two epidemics.
Torralba M. Torralba M. Enferm Infecc Microbiol Clin (Engl Ed). 2021 Oct;39(8):369-371. doi: 10.1016/j.eimce.2021.06.001. Enferm Infecc Microbiol Clin (Engl Ed). 2021. PMID: 34620472 No abstract available.
204 results